JANSSEN PHARMACEUTICALS, INC.

INVEGA TRINZA

Manufacturer:

JANSSEN PHARMACEUTICALS, INC.

Invega Trinza HCPCS:

J2427

HCPCS Code Descriptor:

Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg

Category:

J Code

Invega Trinza NDCs:

50458-0607-01, 50458-0608-01, 50458-0606-01, 50458-0609-01, 50458-0611-01, 50458-0612-01

Primary Type:

Psychiatric

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Invega Trinza:

INVEGA TRINZA is a Psychiatric drug manufactured by JANSSEN PHARMACEUTICALS, INC. and administered via the Intramuscular route of administration. The J Code: J2427 is aligned to the drug INVEGA TRINZA.

Invega Trinza is an antipsychotic medication that may be used to treat schizophrenia. It is an extended drug that is administered one every three months. This may be preferable to patients who have difficulty remembering to take daily medication. Invega Trinza is thought to work by adjusting the levels of dopamine and serotonin in your brain. This may help correct the imbalances that are seen in patients with schizophrenia, thus helping them maintain more stable moods.

ACCESS PRICING AND MORE BY REGISTERING

J2427 Added Date:

July 1, 2023

J2427 Effective Date:

July 1, 2023

J2427 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Invega Trinza billing and coding information.
Invega Trinza patient assistance information can be found through Janssen CarePath at the URL: https://www.invegatrinzahcp.com/patient-support/access-and-affordability
INVEGA TRINZA prescribing information can be found at the link below:
Information regarding INVEGA TRINZA’s side effects can be found at MedlinePlus